网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
加巴喷汀联合依帕司他治疗糖尿病痛性神经病变的效果
作者:李阳  孔彩霞  肖方喜  彭聪  段苗  周杨 
单位:武汉市第一医院 内分泌科, 湖北 武汉 430022
关键词:加巴喷丁 依帕司他 糖尿病痛性神经病变 疗效 安全性 
分类号:R587.2
出版年·卷·期(页码):2019·47·第八期(935-939)
摘要:

目的:研究加巴喷丁联合依帕司他治疗糖尿病痛性神经病变的疗效及安全性。方法:90例糖尿病痛性神经病变患者随机分为观察组和对照组(各45例),对照组患者在常规治疗基础上给予依帕司他治疗,观察组患者在常规治疗基础上给予加巴喷丁联合依帕司他治疗,连续治疗4周。记录治疗有效率。分别于治疗前后采用神经病变症状评分量表(TSS)对神经症状进行评分;采用肌电图仪测定患者正中神经和腓神经感觉传导速度(SCV)和运动传导速度(MCV);分别于治疗前后采用生活质量量表(QOL)进行生活质量评分;记录患者治疗期间不良反应发生情况。结果:观察组疗效显著高于对照组(93.33%vs 73.33%,P<0.05);观察组患者TSS评分显著低于对照组(P<0.05),神经传导速度MCV和SCV值均显著高于对照组(P<0.05);观察组QOL评分显著高于对照组(P<0.05),两组不良反应无显著性差异(P>0.05)。结论:加巴喷丁联合依帕司他可以有效缓解糖尿病痛性神经病变疼痛症状,改善神经传导速度,提高疗效,且无明显不良反应。

Objective:To study the efficacy and safety of gabapentin combined with epalrestat in the treatment of diabetic neuropathy.Methods:A total of 90 patients with diabetic pain neuropathy were randomly divided into observation group and control group (45 cases in each). Patients in the control group were treated with epalrestat on top of routine treatment. Patients in observation group were given gabapentin plus Epalrestat treatment on top ofroutine treatment, continuouslyfor 4 weeks. Neurological symptoms were scored before and after treatment with neurological symptom score scale (TSS); sensory conduction velocity (SCV) and motor conduction velocity (MCV) of median nerve and phrenic nerve were measured by electromyography; before and after treatment quality of life (QOL) scores were used to assess the quality of life; adverse events during treatment were recorded.Results:The curative effect of the observation group was significantly higher than that of the control group (93.33% vs 73.33%, P<0.05). The TSS score of the observation group was significantly lower than that of the control group (P<0.05). The nerve conduction velocity MCV and SCV values were significantly higher thanthose of the control group (P<0.05). The QOL scores in the observation group were significantly higher than those of the control group (P<0.05). There was no significant difference in the adverse reactions between the two groups (P>0.05).Conclusion:Gabapentin combined with epalrestat can effectively relieve the pain symptoms of diabetic pain neuropathy, improve nerve conduction velocity, and improve the efficacy without obvious adverse reactions.

参考文献:

[1] 靳思思,靳绵绵.神经妥乐平联合中药治疗痛性糖尿病神经病变患者的疗效及对血清NO、BDNF和脂联素的影响分析[J].内科,2018,13(1):39-41.
[2] 刘新明,李全民.糖尿病痛性神经病变的治疗新进展[J].临床药物治疗杂志,2017,15(11):1-4.
[3] BENNETT M I,SIMPSON K H.Gabapentin in the treatment of neuropathic pain[J].Palliat Med,2004,18(1):5-11.
[4] NAKAYAMA M,NAKAMURA J,HAMADA Y,et al.Aldose reductase inhibition ameliorates papillary light reflex and F wave latency in patients with mild diabetic neuropathy[J].Diabetes Care,2001,24(6):1093-1098.
[5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,6(7):447-498.
[6] 龙可,朱凯云,闵珊,等.加巴喷丁与卡马西平治疗糖尿病痛性神经病变的临床疗效对比观察[J].吉林医学,2018,39(3):477-478.
[7] 于秀娟,黄昭瑄,马保新.普瑞巴林与加巴喷丁治疗糖尿病痛性神经病变的临床对照研究[J].中国疼痛医学杂志,2015,21(3):231-233.
[8] 杨丕坚,李舒敏,吕以培,等.鼠神经生长因子治疗糖尿病痛性神经病变疗效观察[J].中华实用诊断与治疗杂志,2013,27(6):589-591.
[9] 金星,吴锦丹.糖尿病痛性神经病变的研究进展[J].医学研究生学报,2013,26(5):556-558.
[10] 张岱,王佑民.糖尿病痛性神经病变[J].安徽医药,2011,15(12):1595-1598.
[11] ABBOTT C A,MALIK R A,VAN E,et al.Prevalence and characteristics of painful diabetic neurapathy in a large community-based diabetic population in the UK[J].Diabetes Care,2011,34(10):2220-2224.
[12] 解为慈.2型糖尿病合并痛性神经病变患者应用甲钴胺不同用药方式治疗的疗效及神经传导机制分析[J].神经损伤与功能重建,2018,13(1):48-50.
[13] 郑琪蓉,苏青.依帕司他的药理作用及临床应用[J].中国新药与临床杂志,2006,25(11):876-884.
[14] 沈巍,王丽娜.依帕司他治疗糖尿病痛性神经病变的临床疗效观察[J].中国疼痛医学杂志,2014,20(9):683-684.
[15] DEVI P,MADHU K,GANAPATHY B,et al.Evaluation of efficacy and safety of gabapentin,duloxetine,and pregabalin in patients with painful diabetic peripheral neuropathy[J].Indian J Pharmacol,2012,44(1):51-56.
[16] 朱志刚,郭向阳.加巴喷丁治疗糖尿病痛性神经病变的疗效观察[J].中国实用神经疾病杂志,2014,16(1):41-42.
[17] 龙可,朱凯云,闵珊,等.加巴喷丁与卡马西平治疗糖尿病痛性神经病变的临床疗效对比观察[J].吉林医学,2018,39(3):477-478.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 729580 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541